Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral Mucositis Patient Provider Advisory Board

被引:48
作者
Bellm, LA
Cunningham, G
Durnell, L
Eilers, J
Epstein, JB
Fleming, T
Fuchs, HJ
Haskins, MN
Horowitz, MM
Martin, PJ
McGuire, DB
Mullane, K
Oster, G
机构
[1] IntraBiot Pharmaceut Inc, Mountain View, CA 94043 USA
[2] Vashon, Washington, DC USA
[3] Grove Consultants Int, San Francisco, CA USA
[4] Univ Hosp, Nebraska Hlth Syst, Omaha, NE USA
[5] Univ Washington, Dept Oral Med, Seattle, WA 98195 USA
[6] Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada
[7] Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Milwaukee, WI 53226 USA
[8] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[9] Univ Penn, Philadelphia, PA 19104 USA
[10] Policy Anal Inc, Boston, MA USA
关键词
D O I
10.1081/CNV-120002497
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oral mucositis (OM)-related outcomes constituting a meaningful clinical advance in bone marrow transplant patients were considered by an interdisciplinary panel. Meaningful outcomes are essential in product development for OM, a condition without effective prevention or treatment. The most important outcomes to measure, the feasibility of measuring these in a clinical trial, and clinically meaningful differences in these outcomes were determined by the panel. Most important are reduction in oral pain and use of opioid analgesics, improvement in oral intake and quality of life, and reduction of hospitalization duration. Reduction in the severity of OM measured by an objective evaluation of oral mucosa could provide insight regarding the biologic activity of an intervention. Further data are required to define the precise relationship between reduction in visible OM and improvement in outcome. Minimally, clinical trials for OM should assess oral pain, opioid use, oral intake, and include objective assessment of OM.
引用
收藏
页码:793 / 800
页数:8
相关论文
共 47 条
[1]  
AHMED T, 1993, BONE MARROW TRANSPL, V12, P131
[2]   PROLONGED CONTINUOUS-INFUSION OF CARBOPLATIN AND CONCOMITANT RADIOTHERAPY IN ADVANCED HEAD AND NECK-CANCER - A PHASE-I STUDY [J].
AUSILICEFARO, G ;
MARMIROLI, L ;
NARDONE, L ;
SALVI, G .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (03) :273-276
[3]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[4]  
Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33
[5]   ORAL CAPSAICIN PROVIDES TEMPORARY RELIEF FOR ORAL MUCOSITIS PAIN SECONDARY TO CHEMOTHERAPY RADIATION-THERAPY [J].
BERGER, A ;
HENDERSON, M ;
NADOOLMAN, W ;
DUFFY, V ;
DOOPER, D ;
SABERSKI, L ;
BARTOSHUK, L .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1995, 10 (03) :243-248
[6]  
Berger A M, 1998, Oncol Nurs Forum, V25, P1623
[7]  
Borowski B, 1994, Eur J Cancer B Oral Oncol, V30B, P93, DOI 10.1016/0964-1955(94)90059-0
[8]   TANDEM AUTOTRANSPLANTATION FOR THE TREATMENT OF METASTATIC BREAST-CANCER [J].
BROUN, ER ;
SRIDHARA, R ;
SLEDGE, GW ;
LOESCH, D ;
KNEEBONE, PH ;
HANNA, M ;
HROMAS, R ;
CORNETTA, K ;
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2050-2055
[9]   HERPES-SIMPLEX VIRUS AND ORAL MUCOSITIS IN CHILDREN WITH CANCER [J].
CARREGA, G ;
CASTAGNOLA, E ;
CANESSA, A ;
ARGENTA, P ;
HAUPT, R ;
DINI, G ;
GARAVENTA, A .
SUPPORTIVE CARE IN CANCER, 1994, 2 (04) :266-269
[10]  
CHAPKO MK, 1989, BONE MARROW TRANSPL, V4, P181